Clinical trials

Compound	NCT Number	Status	Phases	Study title	Conditions	URL
ruxolitnib	NCT04281498	Not yet recruiting	Phase 2	Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation	Accelerated/Blast-phase Myeloproliferative Neoplasm\|Chronic-phase Myelofibrosis\|IDH2 Mutation	https://ClinicalTrials.gov/show/NCT04281498